Antitumor activity of tumor necrosis factor-α conjugated with polyvinylpyrrolidone on solid tumors in mice

Cancer Research

Volumn 60, Issue 22, 2000, Pages 6416-6420

  Kamada, H ^a   Tsutsumi, Y ^a   Yamamoto, Y ^a   Kihira, T ^a   Kaneda, Y ^a   Mu, Y ^a   Kodaira, H ^a   Tsunoda, S I ^a   Nakagawa, S ^a   Mayumi, T ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL; POVIDONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG HALF LIFE; DRUG STABILITY; GLYCATION; MALE; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; FEMALE; FIBROSARCOMA; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PHARMACEUTIC AIDS; POLYETHYLENE GLYCOLS; POVIDONE; SARCOMA 180; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033677243     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. An endotoxin-induced serum factor causes necrosis tumor
2. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor
3. Crucial role of 55-kilodalton TNF receptor in TNF-induced adhesion molecule expression and leukocyte organ infiltration
4. Modulation of endothelial cell hemostatic properties by tumor necrosis factor
5. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induced release of interleukin 1
6. 3 in the disruption of the tumor vasculature induced by TNF and IFN-γ
7. Phase I study of recombinant tumor necrosis factor in cancer patients
8. Phase I clinical trial of recombinant human tumor necrosis factor
9. Phase I clinical trial of recombinant human recombinant tumor necrosis factor in children with refractory solid tumors: A pediatric oncology group study
10. Gene therapy for cancer
11. Phase I study of recombinant human tumor necrosis factor
12. Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor α for the treatment of malignant gliomas
13. Polymers for delivering peptides and proteins
14. The clinical efficacy of poly(ethylene glycol)-modified proteins
15. The therapeutic value of poly(ethylene glycol)-modified proteins
16. Molecular design of hybrid turnout necrosis factor-α. II. The molecular size of polyethylene glycol-modified turnout necrosis factor-α affects its anti-tumour potency
17. Molecular design of hybrid tumour necrosis factor α with polyethylene glycol increases its anti-tumour potency
18. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-α: A novel polymer-conjugation technique with a reversible amino-protective reagent
19. Molecular design of hybrid tumor necrosis factor-α III: Polyethylene glycol-modified tumor necrosis factor-α has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor-accumulation
20. Proposal of standardized methods and references for assaying recombinant human tumor necrosis factor
21. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice
22. Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease
23. Localization of the active site of human turnout necrosis factor (hTNF) by mutational analysis
24. Bioconjugation of tumor necrosis factor-α with the copolymer of divinyl ether and maleic anhydride increasing its antitumor potency
25. Antitumor activity of tumor necrosis factor a conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice
26. Divinyl ether-maleic anhydride (pyran) copolymer used to demonstrate the effect of molecular weight on biological activity
27. Evaluation of the immunological and toxicological properties of MVE-2 in Phase I trials
28. Polyvinylpyrrolidone (PVP), its diagnostic, therapeutic and technical application and consequences thereof
29. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy
30. Toxicity and antitumor activity against solid tumors of Micelle-forming polymeric anticancer drug, and its extremely long circulation in blood
31. Tumor tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma
32. Toxic effect of tumor necrosis factor on tumor vasculature in mice
33. Recombinant human tumor necrosis factor-α: Thrombus formation is a cause of antitumor activity
34. Combinations of low concentrations of cytokines and acute agonists synergize in increasing the permeability of endothelial monolayers
35. Selective enhancement by tumor necrosis factor-α of vascular permeability of new blood vessels induced with agarose hydroge,-entrapped Meth-A fibrosarcoma cells
36. Augmentation for intratumoral accumulation and antitumor activity of liposome-encapsulated Adriamycin by tumor necrosis factor-α in mice